"We are pleased with the preliminary findings from our ongoing Phase 2a trial," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "The optimized gel formulation was designed to improve the patient experience, with both easier dispensation and skin application. The expansion of this psoriasis study continues our evaluation of synthetic hypericin into other disease indications, including non- orphan indications, where there remains an unmet medical need. Current estimates ...